Pan-Genotypic Hepatitis C Treatment with Glecaprevir and Pibrentasvir for 8 Weeks Resulted in Improved Cardiovascular and Metabolic Outcomes and Stable Renal Function: A Post-Hoc Analysis of Phase 3 Clinical Trials. [electronic resource]
Publication details: Infectious diseases and therapy Dec 2018Description: 473-484 p. digitalISSN:- 2193-8229
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.